EichorEICHOR
Condition: Chronic Myelocytic Leukemia Synced from ClinicalTrials.gov · August 05, 2026

Recruiting studies: Chronic Myelocytic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in C
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06236724ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 · 1 location(s) · Leland Metheny · NCT06680661Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Phase 2 · 1 location(s) · Korean Society of Hematology · NCT06368414A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT05367700Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Study to Evaluate the Safety and Tolerability of EP0042
Phase 1/Phase 2 · 6 location(s) · Ellipses Pharma · NCT04581512Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligi
Phase 2 · 6 location(s) · Novartis Pharmaceuticals · NCT06514534A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participa
Phase 1/Phase 2 · 54 location(s) · Terns, Inc. · NCT06163430Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT01890486Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Out
Phase N/A · 17 location(s) · Novartis Pharmaceuticals · NCT07091019(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Phase 2 · 42 location(s) · Cogent Biosciences, Inc. · NCT04996875Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT05439889Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03683433Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
Phase N/A · 4 location(s) · Novartis Pharmaceuticals · NCT06684964Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Phase 2 · 8 location(s) · Imperial College London · NCT06355583MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Phase 1/Phase 2 · 39 location(s) · Novartis Pharmaceuticals · NCT04925479Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05805605Second STOP After Pioglitazone Priming in CML Patients
Phase 2 · 6 location(s) · Versailles Hospital · NCT02889003A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients Wit
Phase N/A · 1 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT07061145Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogen
Phase 1/Phase 2 · 6 location(s) · Heinrich-Heine University, Duesseldorf · NCT05807932Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03263572A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Phase N/A · 70 location(s) · Children's Oncology Group · NCT05702645Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Phase N/A · 745 location(s) · Alliance for Clinical Trials in Oncology · NCT05334069ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Phase 1 · 4 location(s) · Enliven Therapeutics · NCT06787144
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.